Compare Recursion Pharmaceuticals Inc (RXRX) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Snap On Incorporated — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B), while Snap On Incorporated trades at $377.53 (market cap $19.65B). The key difference: Snap On Incorporated is far larger — about 10.6× Recursion Pharmaceuticals Inc's market cap, and Snap On Incorporated pays a 2.57% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | SNA | |
|---|---|---|
Market Cap | $1.86B | $19.65B |
Sector | Health | Technology |
52-Week High | $6.79 | $419.31 |
52-Week Low | $2.84 | $324.16 |
Enterprise Value | $1.38B | $19.28B |
Dividend Yield | — | 2.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Snap-On Incorporated (SNA) trades at $379.88, down 0.81% with bearish technical signals but strong fundamentals. The stock shows solid profitability with 19.6% net margins and 17.58% ROE, supported by consistent earnings beats in recent quarters. Recent institutional activity shows mixed positioning while analyst consensus remains bullish with a $473 price target representing 24.5% upside potential.
SNA presents a compelling value opportunity with premium valuation metrics balanced by robust cash flow generation and dividend stability. Key risks include integration challenges from recent acquisitions and potential margin pressure from rising costs. The stock's current technical weakness may offer entry points for long-term investors seeking quality industrial exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
